Ying-Ren Wang

Ying-Ren Wang

Auto-generated profile, based on publicly available information

Ying-Ren Wang

Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei, 10051, Taiwan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
CWChyuan-Chuan Wu
Chyuan-Chuan Wu
YLYi-Ching Li
Yi-Ching Li
YWYing-Ren Wang
Ying-Ren Wang
TLTsai-Kun Li
Tsai-Kun Li
NCNei-Li Chan
Nei-Li Chan
Type II topoisomerases (Top2s) alter DNA topology via the formation of an enzyme–DNA adduct termed cleavage complex, which harbors a transient double-strand break in one DNA to allow the passage of another. Agents targeting human Top2s are clinically active anticancer drugs whose trapping of Top2-mediated DNA breakage effectively induces genome fragmentation and cell death. To understand the structural basis of this drug action, we previously determined the structure of human Top2 β-isoform forming a cleavage complex with the drug etoposide and DNA, and described the insertion of drug into DNA cleavage site and drug-induced decoupling of catalytic groups. By developing a post-crystallization drug replacement procedure that simplifies structural characterization of drug-stabilized cleavage complexes, we have extended the analysis toward other structurally distinct drugs, m-AMSA and mitoxantrone. Besides the expected drug intercalation, a switch in ribose puckering in the 3′-nucleotide of the cleavage site was robustly observed in the new structures, representing a new mechanism for trapping the Top2 cleavage complex. Analysis of drug-binding modes and the conformational landscapes of the drug-binding pockets provide rationalization of the drugs’ structural-activity relationships and explain why Top2 mutants exhibit differential effects toward each drug. Drug design guidelines were proposed to facilitate the development of isoform-specific Top2-targeting anticancer agents.

6 August 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
SCShin-Fu Chen
Shin-Fu Chen
NHNan-Lan Huang
Nan-Lan Huang
JLJung-Hsin Lin
Jung-Hsin Lin
CWChyuan-Chuan Wu
Chyuan-Chuan Wu
YWYing-Ren Wang
Ying-Ren Wang
NCNei-Li Chan
Nei-Li Chan
Type IIA topoisomerases (Top2s) manipulate the handedness of DNA crossovers by introducing a transient and protein-linked double-strand break in one DNA duplex, termed the DNA-gate, whose opening allows another DNA segment to be transported through to change the DNA topology. Despite the central importance of this gate-opening event to Top2 function, the DNA-gate in all reported structures of Top2-DNA complexes is in the closed state. Here we present the crystal structure of a human Top2 DNA-gate in an open conformation, which not only reveals structural characteristics of its DNA-conducting path, but also uncovers unexpected yet functionally significant conformational changes associated with gate-opening. This structure further implicates Top2’s preference for a left-handed DNA braid and allows the construction of a model representing the initial entry of another DNA duplex into the DNA-gate. Steered molecular dynamics calculations suggests the Top2-catalyzed DNA passage may be achieved by a rocker-switch-type movement of the DNA-gate.

15 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CKChung-Yu Ku
Chung-Yu Ku
YWYing-Ren Wang
Ying-Ren Wang
HLHsuan-Yuan Lin
Hsuan-Yuan Lin
SLShao-Chun Lu
Shao-Chun Lu
JLJung-Yaw Lin
Jung-Yaw Lin
Inhibition of VEGFR2 activity has been proposed as an important strategy for the clinical treatment of hepatocellular carcinoma (HCC). In this study, we identified corosolic acid (CA), which exists in the root of Actinidia chinensis, as having a significant anti-cancer effect on HCC cells. We found that CA inhibits VEGFR2 kinase activity by directly interacting with the ATP binding pocket. CA down-regulates the VEGFR2/Src/FAK/cdc42 axis, subsequently decreasing F-actin formation and migratory activity in vitro. In an in vivo model, CA exhibited an effective dose (5 mg/kg/day) on tumor growth. We further demonstrate that CA has a synergistic effect with sorafenib within a wide range of concentrations. In conclusion, this research elucidates the effects and molecular mechanism for CA on HCC cells and suggests that CA could be a therapeutic or adjuvant strategy for patients with aggressive HCC.

1 February 2013 in Current Opinion in Structural Biology
Verified
Journal Article
Closed access
CCChih-Chiang Chang
Chih-Chiang Chang
YWYing-Ren Wang
Ying-Ren Wang
SCShin-Fu Chen
Shin-Fu Chen
CWChyuan-Chuan Wu
Chyuan-Chuan Wu
NCNei-Li Chan
Nei-Li Chan